<DOC>
	<DOCNO>NCT00478023</DOCNO>
	<brief_summary>The main objective study demonstrate efficacy safety multiple-dose application three different oral dos CG5503 IR ( tapentadol immediate release ) compare placebo woman undergo abdominal hysterectomy .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Tapentadol ( CG5503 ) Treatment Acute Pain After Abdominal Hysterectomy</brief_title>
	<detailed_description>Subjects undergoing abdominal hysterectomy often experience moderate severe acute pain post-surgery . Normally pain controlled subject receive repeat dos opioid analgesic . However , opioid therapy commonly associate side effect nausea , vomit , sedation , constipation , addiction , tolerance , respiratory depression . Tapentadol ( CG5503 ) , newly synthesize drug immediate release ( IR ) formulation , also act centrally act pain reliever dual mode action . The aim study investigate effectiveness ( level pain control ) safety ( side effect ) 3 dose level CG5503 IR compare drug ( placebo ) one dose level morphine ( opioid commonly use treat post-surgical pain ) . This study randomize , double-blind ( neither investigator patient know treatment receive ) , active- placebo-controlled , parallel-group , multicenter study evaluate treatment acute pain abdominal hysterectomy . The study include blind 72 hour in-patient phase immediately follow hysterectomy , subject treat either 50- , 75- , 100-mg CG5503 IR , match placebo , 20-mg morphine , pain relief periodically assess . Assessments pain relief include pain intensity numeric rating scale ( PI ) , pain relief numeric rating scale ( PAR ) , patient global impression change scale ( PGIC ) . Safety evaluation include monitor adverse event , physical examination , clinical laboratory test . Venous blood sample collect determination serum concentration CG5503 morphine . The alternative study hypothesis least 1 dose strength CG5503 different placebo control pain 24 hour ( use mean SPID 24 hour ) .</detailed_description>
	<mesh_term>Morphine</mesh_term>
	<criteria>Female 18 80 year age ; Scheduled undergo abdominal hysterectomy without bilateral salpingooophorectomy due uterine leiomyoma , dysfunctional uterine bleed endometrial hyperplasia ; Anesthesiological surgical procedure perform accord protocol ; Moderate severe baseline pain follow hysterectomy Verbal Rating Scale ( VRS ) within 6 hour follow last possible application morphine subcutaneous ; Pain follow hysterectomy least 4 11point Numeric Rating Scale ( NRS ) within 6 hour follow last possible application morphine subcutaneous ; American Society Anesthesiologists ( ASA ) classification IIII . Vaginal hysterectomy ; Ongoing know history painful endometriosis ; Known suspect chronic pelvic pain syndrome ; Previous abdominal pelvic open surgery ; History seizure disorder epilepsy ; History alcohol drug abuse ; Evidence active infection may spread area body ; severely impair renal function , moderately severely impaired hepatic function , Allergy hypersensitivity oxycodone , morphine , fentanyl hydromorphone , heparin , compound plan used anesthesia ; Serious complication surgery randomization ; Preoperative use within 12hours prior surgery perioperative use nonsteroidal antiinflammatory drug ( NSAIDs ) ; Treated regularly opioid analgesic nonsteroidal antiinflammatory drug ( NSAIDs ) within 30 day prior screen ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Opioid</keyword>
	<keyword>Central act analgesic</keyword>
	<keyword>Pain postoperative</keyword>
	<keyword>Abdomen acute</keyword>
	<keyword>CG5503 IR</keyword>
	<keyword>Morphine</keyword>
	<keyword>Placebo</keyword>
</DOC>